(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 September 2012 (20.09.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/125510 A1

(51) International Patent Classification:
A61K 31/4184 (2006.01) *A61K 39/00* (2006.01)
A61K 31/4439 (2006.01) *A61P 35/00* (2006.01)
A61K 31/52 (2006.01) *A61P 35/02* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/US2012/028654

(22) International Filing Date:
9 March 2012 (09.03.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/452,034 11 March 2011 (11.03.2011) US
61/493,317 3 June 2011 (03.06.2011) US

(71) Applicant *(for all designated States except US)*: **GILEAD CALISTOGA LLC** [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GALLATIN, Michael** [US/US]; 8412 SE 33rd Place, Mercer Island, WA 98040 (US). **ULRICH, Roger, G.** [US/US]; 22525 SE 46th Place, Seattle, WA 98075 (US). **GIESE, Neill, A.** [US/US]; 801 Pine Street, Apt. 25A, Seattle, WA 98101 (US). **LANNUTTI, Brian** [US/US]; 305 16th Avenue, Seattle, WA 98121 (US). **YU, Albert** [US/US]; 14831 88th Avenue Ne, Kenmore, WA 98028 (US). **MILLER, Langdon** [US/US]; 13 Strawberry Lane, Lebanon, NJ 08833 (US). **JAHN, Thomas, M.** [DE/US]; 2448 29th Avenue West, Seattle, WA 98199 (US).


(74) Agents: **LIANG, Catherine, O.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,


[Continued on next page]

(54) Title: COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES

(57) Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R' is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximab, and ofatumumab.




(A)



(B)

Figure 40



(A)

WO 2012/125510 A1

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*